UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) May 8, 2017 (May 5, 2017)
LUCKYCOM PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
|
Nevada
|
333-187874
|
46-1660653
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
| 11767 Katy Freeway, Suite 830, Houston, Texas | 77079 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, include area code 281-668-8266
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K fi ling is intended to simultaneously satisfy the fi ling obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 3.02
|
Unregistered Sales of Equity Securities
|
On May 5, 2017, Luckycom Pharmaceuticals Inc. (the “Company”) issued 750,000 shares of common stock to Mr. Kingrich Lee in settlement of the debt owed to Mr. Lee in the amount of $327,504 as of March 31, 2017 and in exchange of Mr. Lee’s investment of $250,000 to the Company and $172,496 to the Company’s wholly owned subsidiary, Luckycom Limited. The issuance of the shares was exempt from registration under the Securities Act of 1933 pursuant to Section 4(a)(2) thereof on the basis that the transaction did not involve a public offering. The shares are subject to restrictions on resale pursuant to Commission Rule 144 under the Securities Act.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
LUCKYCOM PHARMACEUTICALS INC.
|
|||
|
Date: May 8, 2017
|
By:
|
/s/ Kingrich Lee | |
| Name: Kingrich Lee | |||
| Title: Chief Executive Officer and Chief Financial Officer | |||